SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* 2026 First Quarterly Report" published by Shanghai Junshi Biosciences Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for reference purpose only. The unaudited financial data set out in this announcement is prepared in accordance with the accounting principles of the People's Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only. The following is a translation of the 2026 First Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, PRC, 27 April 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purpose only*

Stock code: 688180 Abbreviation: Junshi Bio

Shanghai Junshi Biosciences Co., Ltd.* 2026 First Quarterly Report

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

IMPORTANT NOTICE

The board of directors, the directors and senior management of the Company undertake that the information in this quarterly report is true, accurate and complete, and contains no false record, misleading statement or material omission, and assume several and joint liabilities in respect of the information in this report.

The person in charge of the Company, the person in charge of accounting affairs, and the person in charge of the accounting office (head of accounting department), hereby guarantee that the financial statements contained in this quarterly report are true, accurate and complete.

Whether the financial statements contained in this first quarterly report have been audited
□ Yes √ No

I. Key Financial Data

(I) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Item	During the reporting period	During the corresponding period of the previous year	Change year-on-year (%)
Operating income	726,287,839.60	500,591,459.94	45.09
Total loss	-37,842,584.71	-286,837,114.51	N/A

Net loss attributable to shareholders of the Company	-20,564,028.12	-234,876,226.63	N/A
Net loss attributable to shareholders of the Company after deducting non-recurring profit and loss	-143,609,202.00	-239,469,916.07	N/A
Net cash flow from operating activities	57,849,234.99	-24,331,196.50	N/A
Basic earnings per share (Yuan/share)	-0.02	-0.24	N/A
Diluted earnings per share (Yuan/share)	-0.02	-0.24	N/A
Weighted average return on net assets (%)	-0.34	-4.09	Increased by 3.75 percentage points
Total research and development investment	282,495,448.11	350,575,453.92	-19.42
Research and development investment as a percentage of operating income (%)	38.90	70.03	Decreased by 31.13 percentage points
	As at the end of the reporting period	As at the end of the previous year	Increase/decrease at the end of the reporting period compared with the end of the previous year (%)
Total assets	14,151,999,301.56	12,382,326,895.36	14.29
Owners' equity attributable to the shareholders of the Company	5,896,037,652.78	6,030,434,432.07	-2.23

Note 1: The "Reporting Period" refers to the period of three months commencing from the beginning of this quarter to the end of this quarter, the same for below.

Note 2: After deducting the effect of the share-based payments, the net profit attributable to shareholders of the Company for the reporting period was RMB43,440,300, representing an increase of approximately RMB278,316,500 compared with the corresponding period of the previous year.

(II) Non-recurring gains and losses items and amounts

√ Applicable □ Not applicable

Unit: Yuan Currency: RMB

Non-recurring gains and losses items	Amount for the reporting period	Note
Gains or losses from the disposal of non-current assets, including write-off of provision for asset impairment	138,523,027.88	Nil
Government grants that are recognized in profit or loss for the period (other than government grants which are closely related to the Company's normal business operations, comply with national policies, conform with established standards and have a lasting impact on the Company's profits or losses)	4,486,039.02	Nil
Gains or losses on changes in fair value arising from holding financial assets and liabilities by non-financial enterprises, as well as gains or losses from disposal of financial assets and liabilities, except for effective hedging transactions related to the Company's normal business operations	-10,811,516.74	Nil
Other non-operating income and expenses apart from the aforesaid items	-9,135,914.38	Nil
Less: Effect of income tax	-	Nil
Effect of minority interests (after tax)	16,461.90	Nil
Total	123,045,173.88	Nil

Description on the reasons for recognizing items not set out in the "Explanatory Announcement No. 1 Regarding Information Disclosure for Companies Publicly Issuing Securities - Non-recurring Gains or Losses"* (《公開發行證券的公司信息披露解釋性公告第 1 號——非經常性損益》) as non-recurring gains or losses items and the amounts of which are significant, and defining the non-recurring gains or losses items set out in the "Explanatory Announcement No. 1 Regarding Information Disclosure for Companies Publicly Issuing Securities - Non-recurring Gains or Losses"* (《公開發行證券的公司信息披露解釋性公告第 1 號——非經常性損益》) as recurring gains or losses items by the Company.

□ Applicable √ Not applicable

(III) Descriptions and reasons for changes in major accounting data and financial indicators

√ Applicable □ Not applicable

Item	Change (%)	Major reason
Operating income	45.09	Mainly due to the growth of sales revenue from commercialized drugs and the increase in operating income as compared with the corresponding period of the previous year.
Research and development investment as a percentage of operating income (%)	Decreased by 31.13 percentage points	
Total loss	N/A	Mainly due to the growth of sales revenue from the Company's commercialized drugs as compared with the corresponding period of the previous year. Meanwhile, the Company actively implemented the action plan for "Enhancing Quality and Efficiency with a Focus on Return" to improve the efficiency of research and development ("R&D") and sales, resulting in a decrease in loss.
Net loss attributable to shareholders of the listed company	N/A	
Net loss attributable to shareholders of the Company after deducting non-recurring profit and loss	N/A	
Basic earnings per share (Yuan/share)	N/A	
Diluted earnings per share (Yuan/share)	N/A	
Net cash flow from operating activities	N/A	Mainly due to the growth of sales revenue from commercialized drugs and the increase in cash inflows from operating activities as compared with the corresponding period of the previous year.

II. Shareholder Information

(I) Particulars of total number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of top ten shareholders

Unit: Share

<table>
<tr><td colspan="2">Total number of ordinary shareholders as at the end of the reporting period</td><td>38,184</td><td colspan="3">Total number of preferred shareholders with voting rights restored as at the end of the reporting period (if any)</td><td>N/A</td></tr>
<tr><td colspan="7">Particulars of shareholding of the top 10 shareholders (excluding the shares lent under securities refinancing)</td></tr>
<tr><td>Name of shareholder</td><td></td><td>Number of shares held</td><td>Shar ehold</td><td>Numb er of</td><td>Number of</td><td>Pledged, marked or frozen shares</td></tr>
</table>

	Type of shareholder		ing percentage (%)	shares held subject to trading restrictions	restricted shares including shares lent for securities refinancing	Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	260,291,040	25.35	0	0	Unknown	-
Xiong Jun	Domestic natural person	90,218,913	8.79	0	0	Nil	0
Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合夥企業(有限合夥))	Others	59,459,326	5.79	0	0	Nil	0
Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業(有限合夥))	Others	43,584,000	4.25	0	0	Nil	0
Xiong Fengxiang	Domestic natural person	41,060,000	4.00	0	0	Nil	0
Zhou Yuqing	Domestic natural person	21,680,800	2.11	0	0	Nil	0
Feng Hui	Domestic natural person	13,140,000	1.28	0	0	Nil	0
Liu Xiaoling	Domestic natural person	8,608,000	0.84	0	0	Nil	0
Wang Lifang	Domestic natural person	8,608,000	0.84	0	0	Nil	0

Bank of Shanghai Co., Ltd. - Yinhua CSI Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (上海銀行股份有限公司—銀華中證創新藥產業交易型開放式指數證券投資基金)	Others	8,302,954	0.81	0	0	Nil	0

Particulars of shareholdings of the top 10 shareholders not subject to trading restrictions (excluding the shares lent under securities refinancing)			
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Type and number of shares	
		Type of shares	Number of shares
HKSCC NOMINEES LIMITED	260,291,040	Overseas listed foreign shares	260,291,040
Xiong Jun	90,218,913	RMB ordinary shares	90,218,913
Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合夥企業(有限合夥))	59,459,326	RMB ordinary shares	59,459,326
Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業(有限合夥))	43,584,000	RMB ordinary shares	43,584,000
Xiong Fengxiang	41,060,000	RMB ordinary shares	41,060,000
Zhou Yuqing	21,680,800	RMB ordinary shares	21,680,800
Feng Hui	13,140,000	RMB ordinary shares	13,140,000
Liu Xiaoling	8,608,000	RMB ordinary shares	8,608,000
Wang Lifang	8,608,000	RMB ordinary shares	8,608,000

Bank of Shanghai Co., Ltd - Yinhua CSI Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (上海銀行股份有限公司—銀華中證創新藥產業交易型開放式指數證券投資基金)	8,302,954	RMB ordinary shares	8,302,954
Description of the related party relationship or acting-in-concert arrangement among the above shareholders	Among the above shareholders, Xiong Fengxiang and Xiong Jun have a father-son relationship and are the controlling shareholders and actual controllers of the Company. Xiong Jun and Xiong Fengxiang are acting in concert with Zhou Yuqing, Liu Xiaoling and Wang Lifang. Xiong Jun holds 40% of the equity interest in Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.* (深圳前海源本股權投資基金管理有限公司), being the managing partner of Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業(有限合夥)) ("Ruiyuan Shengben"). Ruiyuan Shengben is held as to 5.1% by Zhou Yuqing. Save for the above description, the Company is not aware as to whether the other shareholders have related party relationship or whether the other shareholders are acting in-concert parties under relevant regulations.		
Description on the top 10 shareholders and the top 10 shareholders not subject to trading restrictions engaging in margin trading and securities refinancing, if any	Nil		

Note 1: As at the end of the reporting period, among all the ordinary shareholders, there are 38,172 holders of A shares and 12 holders of H shares, amounting to a total of 38,184 shareholders;
Note 2: HKSCC NOMINEES LIMITED holds shares on behalf of various clients.

Shares lent by shareholders interested in more than 5% of the shares, top 10 shareholders and top 10 shareholders not subject to trading restrictions for securities refinancing
□ Applicable √ Not applicable

Change in top 10 shareholders and top 10 shareholders not subject to trading restrictions as compared to the prior period due to lending/returning of shares for securities refinancing
□ Applicable √ Not applicable

III. Other Significant Information

Other significant information about the operations of the Company during the reporting period that requires investors' attention
√ Applicable □ Not applicable

During the reporting period, the growth of the operating revenue of the Company was primarily attributable to the growth of sales revenue of commercialized drugs. In particular, the core product, toripalimab injection (trade name: TUOYI®/LOQTORZI®, product code: JS001) recorded sales revenue of approximately RMB623 million in the domestic market, representing a year-on-year increase of approximately 39.37%. At the same time, the Company actively implemented the action plan for “Enhancing Quality and Efficiency with a Focus on Return” to improve the efficiency of R&D and sales, resulting in continued optimization of its operating quality and a decrease in loss as compared to the same period last year. After deducting the effect of the share-based payments, the net profit attributable to shareholders of the Company for the reporting period was RMB43,440,300. As of the end of the reporting period, the Company’s cash and bank balances and financial assets for trading had a total balance of RMB4,561 million, demonstrating relatively sufficient capital reserves.

Since 1 January 2026, two new indications of TUOYI® and ongericimab injection* (trade name: JUNSHIDA (君適達®)) have been included in the National Drug Catalogue for Basic Medical Insurance, Maternity Insurance and Work Related-Injury Insurance (2025) (the “NRDL”). All four commercialized products of the Company have been included in the NRDL, which will continuously enhance the commercialization capabilities of the Company across different tumor types or disease areas. As of the date of this report, the indications of toripalimab for the first-line treatment of nasopharyngeal carcinoma and the first-line treatment of esophageal squamous cell carcinoma were approved for marketing in Oman and Qatar, and the new indication for toripalimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma was approved in Singapore. Toripalimab has been approved for marketing in more than 40 countries and regions, including China, the United States and the EU. During the reporting period, the new drug applications for toripalimab injection (subcutaneous injection) (JS001sc) for 12 indications in the treatment of tumors have been accepted by the National Medical Products Administration, marking the first domestic anti-PD-1 monoclonal antibody subcutaneous injection formulation to enter the marketing application stage.

During the reporting period, the Company continued to enhance resource focus to rapidly advance clinical trials for multiple innovative drugs with international market competitiveness, including the PD-1/VEGF bispecific antibody (JS207), the EGFR/HER3 ADC (JS212) and the PD-1/IL-2 fusion protein (JS213). Furthermore, it actively explored multiple combination regimens to maximize pipeline synergies and enhance its competitiveness in the global market.

The Company will maintain its strategic focus on the development of biologics and continue to monitor and conduct in-depth research and exploratory studies on selected targets. It will develop innovative drug candidates to address unmet clinical needs and introduce cutting-edge AI technology platforms to assist in drug design, screening, and optimization, thereby improving R&D efficiency, shortening R&D cycles and reducing R&D costs. Meanwhile, the Company will continue to enhance its commercial competitiveness, accelerate global expansion, and further promote quality and efficiency improvements in operations and management, so as to continuously strengthen its self-sustainability.

IV. Quarterly Financial Statements

(I) Types of audit opinion

□ Applicable √ Not applicable

(II) Financial statements

CONSOLIDATED BALANCE SHEET

31 March 2026

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Item	31 March 2026	31 December 2025
Current assets:		
Cash and bank balances	3,910,705,939.03	2,614,574,505.30
Financial assets for trading	650,444,328.76	600,782,465.75
Notes receivable	-	301,960.00
Accounts receivable	459,673,648.29	506,444,604.30
Prepayments	152,822,830.93	143,908,448.95
Other receivables	122,381,411.93	2,042,946.57
Including: Interests receivable	-	-
Dividends receivable	-	-
Inventories	562,433,441.97	573,109,752.55
Including: Data resources	-	-
Non-current assets due within one year	2,190,909.63	3,148,508.65
Other current assets	13,736,802.19	13,390,319.00
Total current assets	5,874,389,312.73	4,457,703,511.07
Non-current assets:		
Long-term receivables	24,702,970.30	24,702,970.30
Long-term equity investments	466,862,771.00	507,776,438.78
Investments in other equity instruments	60,055,676.60	55,787,175.27
Other non-current financial assets	1,608,144,606.93	1,325,768,477.83
Fixed assets	2,239,205,644.90	2,221,096,731.58
Construction in progress	2,639,496,460.97	2,571,703,428.69
Right-of-use-assets	72,486,441.63	79,593,733.58
Intangible assets	550,688,310.57	559,773,894.39
Including: Data resources	-	-
Long-term prepaid expenses	10,350,564.07	9,759,472.04
Deferred income tax assets	85,246,216.34	88,308,527.36
Other non-current assets	520,370,325.52	480,352,534.47
Total non-current assets	8,277,609,988.83	7,924,623,384.29
Total assets	14,151,999,301.56	12,382,326,895.36
Current liabilities:		
Short-term borrowings	729,112,259.53	603,197,330.31
Accounts payable	1,004,475,158.66	1,142,715,070.58

Contract liabilities	67,898,805.69	22,183,511.42
Payroll payable	268,718,425.19	252,624,342.64
Taxes payable	25,572,028.91	27,142,927.63
Other payables	31,667,057.49	39,011,075.23
Including: Interests payable	-	-
Dividends payable	-	-
Non-current liabilities due within one year	618,818,148.94	691,400,539.86
Other current liabilities	3,236.16	3,236.16
Total current liabilities	2,746,265,120.57	2,778,278,033.83
Non-current liabilities:		
Long-term borrowings	3,577,703,062.96	2,793,607,544.33
Bonds payables	997,175,686.79	-
Including: Preferred shares	-	-
Perpetual debts	-	-
Lease liabilities	52,620,194.91	56,616,357.89
Deferred income	159,885,889.33	167,170,847.81
Other non-current liabilities	528,241,204.84	530,059,830.73
Total non-current liabilities	5,315,626,038.83	3,547,454,580.76
Total liabilities	8,061,891,159.40	6,325,732,614.59
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	1,026,689,871.00	1,026,689,871.00
Capital reserve	16,297,736,522.05	16,417,491,825.28
Less: Treasury shares	30,892,473.08	30,892,473.08
Other comprehensive income	-160,764,706.95	-166,687,259.01
Retained earnings	-11,236,731,560.24	-11,216,167,532.12
Total owners' equity (or shareholders' equity) attributable to the parent company	5,896,037,652.78	6,030,434,432.07
Minority interests	194,070,489.38	26,159,848.70
Total owners' equity (or shareholders' equity)	6,090,108,142.16	6,056,594,280.77
Total liabilities and owners' equity (or shareholders' equity)	14,151,999,301.56	12,382,326,895.36

Legal Representative: Xiong Jun   Chief Financial Officer: Xu Baohong   Head of Accounting Department: Cai Jingwu

CONSOLIDATED INCOME STATEMENT

January to March 2026

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan   Currency: RMB   Audit type: Unaudited

Item	First quarter of 2026	First quarter of 2025
I. Total operating income	726,287,839.60	500,591,459.94
Including: Operating income	726,287,839.60	500,591,459.94
II. Total operating costs	861,878,028.11	782,539,195.35
Including: Operating costs	146,975,372.39	93,900,960.88
Taxes and surcharges	6,137,644.64	5,961,832.38
Selling and distribution expenses	251,772,425.71	225,684,498.88
Administrative expenses	138,640,081.25	97,024,040.85
Research and development expenses	282,495,448.11	350,575,453.92
Financial expenses	35,857,056.01	9,392,408.44
Including: Interest expenses	23,987,870.26	16,807,655.37
Interest income	7,392,058.78	7,407,783.93
Add: Other income	10,803,119.67	6,564,179.02
Investment income (Loss is indicated by “-”)	120,894,987.10	-10,369,937.82
Including: Income from investments in associates and joint ventures	-20,120,432.82	-12,293,727.30
Gain from changes in fair value (Loss is indicated by “-”)	-13,362,009.89	-289,233.84
Impairment loss of credit (Loss is indicated by “-”)	-3,199,702.43	2,588,467.66
Impairment loss of assets (Loss is indicated by “-”)	-8,310,977.38	-5,810,755.08
Gains from disposal of assets (Loss is indicated by “-”)	176,910.96	7,549,150.19
III. Operating profit (Loss is indicated by “-”)	-28,587,860.48	-281,715,865.28
Add: Non-operating income	158,927.36	6,866.57
Less: Non-operating expenses	9,413,651.59	5,128,115.80
IV. Total profit (Total loss is indicated by “-”)	-37,842,584.71	-286,837,114.51
Less: Income tax expenses	5,582,837.13	-27,250,675.73
V. Net profit (Net loss is indicated by “-”)	-43,425,421.84	-259,586,438.78
(I) Categorized by the nature of continuing operation		
1. Net profit from continuing operations (Net loss is indicated by “-”)	-43,425,421.84	-259,586,438.78
2. Net profit from discontinued operations (Net loss is indicated by “-”)	-	-
(II) Categorized by ownership		
1. Net profit attributable to the parent company (Net loss is indicated by “-”)	-20,564,028.12	-234,876,226.63

2. Profit or loss attributable to minority shareholders (Net loss is indicated by "-")	-22,861,393.72	-24,710,212.15
VI. Other comprehensive income, net of tax	5,922,552.06	-10,204,644.58
(I) Other comprehensive income attributable to the parent company, net of tax	5,922,552.06	-10,204,644.58
1．Other comprehensive income that cannot be subsequently reclassified to profit or loss	4,268,501.33	-10,284,894.49
(1) Changes of the re-measurement in defined benefit plans	-	-
(2) Other comprehensive income that cannot be subsequently reclassified to profit or loss under the equity method	-	-
(3) Changes in fair value of investments in other equity instruments	4,268,501.33	-10,284,894.49
(4) Changes in fair value of the enterprise's own credit risk	-	-
2．Other comprehensive income that will be reclassified to profit or loss	1,654,050.73	80,249.91
(1) Other comprehensive income that will be reclassified to profit or loss under the equity method	-	-
(2) Changes in fair value of other debt investments	-	-
(3) Amount of financial assets that are reclassified to other comprehensive income	-	-
(4) Impairment provision for credit of other debt investments	-	-
(5) Cash flow hedge reserves	-	-
(6) Exchange differences of financial statements denominated in foreign currencies	1,654,050.73	80,249.91
(7) Others	-	-
(II) Other comprehensive income attributable to minority shareholders, net of tax	-	-
VII. Total comprehensive income	-37,502,869.78	-269,791,083.36
(I) Total comprehensive income attributable to owners of the parent company	-14,641,476.06	-245,080,871.21

(II) Total comprehensive income attributable to minority shareholders	-22,861,393.72	-24,710,212.15
VIII. Earnings per share:		
(I) Basic earnings per share (Yuan/share)	-0.02	-0.24
(II) Diluted earnings per share (Yuan/share)	-0.02	-0.24

In respect of the merger of entities under common control that occurred during the current period, net profit of the entity being merged realized before the merger was nil. Net profit of the entity being merged realized during the previous period was nil.

Legal Representative: Xiong Jun   Chief Financial Officer: Xu Baohong   Head of Accounting Department: Cai Jingwu

CONSOLIDATED STATEMENT OF CASH FLOW

January to March 2026

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Item	First quarter of 2026	First quarter of 2025
I. Cash flow from operating activities:		
Cash received from the sale of goods and the rendering of services	836,531,206.52	740,358,831.82
Receipts of tax refunds	-	26,804,625.42
Other cash received in respect of operating activities	4,634,382.41	36,256,368.27
Sub-total of cash inflow from operating activities	841,165,588.93	803,419,825.51
Cash payments for goods purchased and services received	394,081,798.57	469,391,325.13
Cash payments to and on behalf of employees	314,545,623.44	292,997,853.30
Payments of various types of taxes	29,296,607.61	27,815,876.75
Other cash payments relating to operating activities	45,392,324.32	37,545,966.83
Sub-total of cash outflow from operating activities	783,316,353.94	827,751,022.01
Net cash flow from operating activities	57,849,234.99	-24,331,196.50
II. Cash flow from investing activities:		
Cash received from recovery of investments	651,000,000.00	481,065,293.22
Cash received from investment income	2,550,493.15	1,781,547.95

Net cash received from disposal of fixed assets, intangible assets and other long-term assets	-	380.00
Other cash received in respect of investing activities	7,392,058.78	7,546,867.69
Sub-total of cash inflow from investing activities	660,942,551.93	490,394,088.86
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	251,907,576.74	161,199,762.48
Cash paid for investments	950,400,002.00	649,000,000.00
Other cash payments relating to investing activities	-	21,820,041.00
Sub-total of cash outflow from investing activities	1,202,307,578.74	832,019,803.48
Net cash flow from investing activities	-541,365,026.81	-341,625,714.62
III. Cash flow from financing activities:		
Cash received from borrowings	1,421,047,188.74	1,421,654,234.10
Cash received from issuance of bonds	1,000,000,000.00	
Other cash received in respect of financing activities	-	676,829.08
Sub-total of cash inflow from financing activities	2,421,047,188.74	1,422,331,063.18
Cash repayments of borrowings	582,300,000.00	997,243,377.50
Cash payments for distribution of dividends, or profits or settlement of interest expenses	28,011,611.35	23,008,576.17
Including: Cash payments for distribution of dividends or profits to minority shareholders of subsidiaries	-	-
Other cash payments relating to financing activities	18,386,914.98	15,301,114.26
Sub-total of cash outflow from financing activities	628,698,526.33	1,035,553,067.93
Net cash flow from financing activities	1,792,348,662.41	386,777,995.25
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-12,144,143.00	-791,648.43
V. Net increase in cash and cash equivalents	1,296,688,727.59	20,029,435.70

Add: Balance of cash and cash equivalents at the beginning of the period	2,593,999,709.74	2,486,679,108.82
VI. Balance of cash and cash equivalents at the end of the period	3,890,688,437.33	2,506,708,544.52

Legal Representative: Xiong Jun
Chief Financial Officer: Xu Baohong
Head of Accounting Department: Cai Jingwu

New accounting standards or interpretations of standards in 2026 involving adjustments made to initial adoption of relevant items of the financial statements as at the beginning of the year

□ Applicable √ Not applicable

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
27 April 2026

* *For identification purpose only*